Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Net Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Net Margin for 3 consecutive years, with 2204.15% as the latest value for Q2 2025.

  • Quarterly Net Margin fell 186021515.0% to 2204.15% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 10083.15% through Dec 2025, up 3136401.0% year-over-year, with the annual reading at 10773.46% for FY2025, 85455946.0% down from the prior year.
  • Net Margin for Q2 2025 was 2204.15% at Inhibrx Biosciences, down from 1610.67% in the prior quarter.
  • The five-year high for Net Margin was 1858011.0% in Q2 2024, with the low at 156840.0% in Q2 2023.
  • Average Net Margin over 3 years is 200566.5%, with a median of 3916.34% recorded in 2025.
  • The sharpest move saw Net Margin soared 201485100bps in 2024, then plummeted -186021515bps in 2025.
  • Over 3 years, Net Margin stood at 5628.52% in 2023, then crashed by -750bps to 47865.0% in 2024, then skyrocketed by 95bps to 2204.15% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 2204.15%, 1610.67%, and 47865.0% for Q2 2025, Q1 2025, and Q4 2024 respectively.